NextCell Pharma AB (DE:65G)

FRANKFURT:65G

65G

NextCell Pharma AB

RESEARCH TOOLSreports

NextCell Pharma AB (65G) Price & Analysis

0 Followers

65G Stock Chart & Stats

€0.05

>-€0.01(-2.19%)

At close: Jan 08 4:00 PM EST

€0.05

>-€0.01(-2.19%)

Day’s Range― - ―

52-Week Range€0.05 - €0.17

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€10.69M

Enterprise Value€86.42M

Total Cash (Recent Filing)€32.33M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta>-0.01

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding111,392,960

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)1.36

Price to Sales (P/S)8.24

P/FCF Ratio-2.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.04

Revenue Forecast (FY)€1.51M

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet (no Debt)Having zero reported debt materially lowers financial risk for a biotech with long clinical timelines. It preserves flexibility to time external financings, reduces fixed interest burden, and supports continued R&D investment even through extended development cycles.

Multi-year Revenue ExpansionSustained revenue growth over multiple years signals commercial traction or progressing clinical activity. That track record supports scalability of operations, improves the case for longer-term funding, and can underpin eventual margin recovery with scale.

Focused Cell-therapy Platform ExpertiseA specialized MSC-based platform creates durable technical expertise and potential intellectual property moats in regenerative medicine. Focused R&D can yield differentiated pipeline assets and partnerships in a high-barrier, fast-growing therapeutic niche.

Bears Say

Large And Persistent Cash BurnConsistently negative operating and free cash flows mean the company must repeatedly access external capital to fund operations. Over the medium term this increases financing risk, raises dilution potential, and can force project reprioritization or delays if markets tighten.

Negative Gross Profit And MarginsNegative gross profit indicates unit economics are currently unprofitable, not just investment-phase SG&A. Without structural changes to cost base or successful high-value product launches, scaling revenue will not translate into sustainable profitability.

Declining Equity And Dilution RiskMaterial declines in equity reflect accumulated losses and reliance on external funding. This shrinks the balance-sheet buffer, raises the likelihood of further capital raises, and creates persistent dilution risk that can erode long-term shareholder value.

65G FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was €0.05 and its highest was €0.17 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is €10.69M.

When is NextCell Pharma AB’s upcoming earnings report date?

NextCell Pharma AB’s upcoming earnings report date is Aug 27, 2026 which is in 67 days.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on May 28, 2026. The company reported -€0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.008.

Is NextCell Pharma AB overvalued?

According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 111,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -€0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in DE:65G

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCell Pharma AB

NextCell Pharma AB operates as a biopharmaceutical enterprise, dedicating its efforts to the groundbreaking research and advancement of novel stem cell-based therapies within Sweden. A significant development from the company is ProTrans, an investigational drug derived from stem cells, primarily formulated to address autoimmune and inflammatory ailments. Beyond therapeutic development, NextCell Pharma AB also offers Cellaviva, a specialized stem cell banking service that enables families to securely preserve stem cells sourced from umbilical cord blood and tissue. Established in 2014, the company maintains its corporate headquarters in Huddinge, Sweden.